Healthcare · Profile from Healthcare Research Companion
Stryker Corporation
The Kalamazoo surgeon's workshop that became one of the largest and most consistent medical technology companies in the world. Stryker sells orthopedic implants (hips, knees, trauma, extremities), the Mako robot that pulls those implants into operating rooms, and a broad MedSurg and neurotechnology portfolio: hospital beds and stretchers, surgical power tools, endoscopy cameras, neurovascular devices, defibrillators and, since 2025, peripheral vascular clot-removal devices from Inari. Its history is a steady sequence of acquisitions and a decades-long target of double-digit growth, interrupted by a costly hip implant recall and, in 2026, one of the most disruptive cyberattacks ever suffered by a medtech company.
At a glance
- Founded
- 1941, Kalamazoo, Michigan, by orthopedic surgeon Dr Homer Stryker (incorporated as the Orthopedic Frame Company in the 1940s; renamed Stryker Corporation in 1964)
- Founder
- Homer H. Stryker, MD
- Headquarters
- Portage (Kalamazoo), Michigan
- Ownership / structure
- Public company, NYSE: SYK (IPO 1979); the Stryker family (notably Ronda Stryker, a long-serving director) remains a significant holder; size of the current family stake not checked here
- Leadership (2026)
- Kevin Lobo, Chair and CEO (CEO since October 2012; Chair since 2014); Preston Wells, CFO (from 2024)
- Segments
- MedSurg and Neurotechnology (instruments, endoscopy, medical — beds, stretchers, emergency care — neurovascular, neurosurgery, ENT, and the Vascular unit built on Inari); Orthopaedics (knees, hips, trauma and extremities, Mako). US spinal implants sold to VB Spine on 1 April 2025; some international spine markets transfer later
- Payer and customer
- Hospitals and ambulatory surgery centers (ASCs) buy, often through GPOs and system contracts; surgeons choose implants; procedures are paid by Medicare (joint replacement is a large Medicare DRG), commercial plans and, abroad, national systems
- Scale
- 2025 net sales ~$25.1bn (+11.2% reported, +10.3% organic); MedSurg and Neurotechnology ~$15.6bn, Orthopaedics ~$9.5bn; adjusted EPS $13.63 (January 2026 release). Q1–Q3 2026 net sales ~$19.1bn (+6.6% reported); 2026 organic guidance cut to 6.5–7.0% in October 2026 after the cyberattack and a weak Q3. ~56,000 employees (company fast facts, end-2025). Mako installed base over 3,000 systems worldwide
- Capital / market cap
- Investment-grade balance sheet; annual dividends since the early 1990s; $1.0bn of buybacks in Q3 2026 and a further $3.0bn authorisation (October 2026); market cap roughly $130–150bn in 2025–26 (approximate, moves with the share price)
- Signature moves (incl. failures)
- Founding and the turning frame (1941); Howmedica from Pfizer (1998); Boston Scientific neurovascular (2011); Rejuvenate/ABG II hip recall and settlements of well over $1.4bn (2012–16); Mako Surgical (2013); Wright Medical (2019–20); Inari Medical and spine exit (2025); Handala wiper cyberattack (2026)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1941
Founding and the Turning Frame
Founding
1998
Howmedica Acquisition
Acquisition
2011
Boston Scientific Neurovascular
Acquisition (carve-out)
2012
Rejuvenate and ABG II Hip Recall
Recall and litigation settlement
2013
Mako Surgical Acquisition
Acquisition
2019
Wright Medical Acquisition
Acquisition
2025
Inari Acquisition and Spine Exit
Acquisition and divestiture (portfolio reshaping)
2026
Handala Wiper Cyberattack
Cyber incident and crisis response